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A B S T R A C T
Purpose: To evaluate the relationship between serum concentrations of mono-hydroxy-carbazepine
(MHD), the main metabolite of oxcarbazepine (OXC), and the occurrence of adverse effects (AE) in a large
group of patients on OXC monotherapy.
Methods: An antiepileptic drug (AED) therapeutic drug monitoring (TDM) database was analyzed
especially with regard to OXC dosage, MHD serum concentration, and the occurrence of AE. In total,
893 blood samples of 442 patients were included in this retrospective study. The statistical evaluation
was performed by means of Kaplan-Meier estimates, log-rank tests and generalized estimating
equations (GEE).
Results: At least one AE was reported in 78 (17.6%) of the 442 patients. At MHD serum concentrations of
30.0 mg/ml and 43.7 mg/ml and OXC dosages of 33.1 mg/kg and 62.3 mg/kg, 25% and 75% of patients,
respectively, experienced at least one AE. Log-rank tests indicated that younger patients (<18 years) may
be able to tolerate higher MHD serum levels (p = 0.006) and higher OXC dosages per body weight
(p < 0.001) compared to adult patients (18 years). Furthermore, AEs occurred at higher body-weight
adjusted OXC dosages of extended release formulations compared to immediate-release formulations
(p = 0.010), whereas MHD serum levels at which AEs occurred did not differ signiﬁcantly between
formulations (p = 0.125). Multivariate GEE conﬁrmed the results.
Conclusion: The occurrence of AEs is signiﬁcantly (and non-linearly) dependent on MHD serum level,
whereas the dependence of OXC dosage is less distinctive. But, tolerability of OXC seems to depend on
age of the patients as well as on pharmaceutical formulation of OXC.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Oxcarbazepine (OXC) is a second-generation antiepileptic drug
(AED) often used for the treatment of focal seizures with and
without secondary generalization. It was approved in Europe in
1999 and since 2000 also in the United States, indicated for the
treatment of adults and children with focal onset seizures as
mono- or adjunctive therapy. In addition to the initially immedi-
ate-release formulations as tablet or suspension there are also
extended-release formulations available in Germany for several
years.* Corresponding author at: Gesellschaft fu¨r Epilepsieforschung, Maraweg 21,
33617 Bielefeld, Germany. Tel.: +49 521 144 2950.
E-mail address: may_gfe@t-online.de (T.W. May).
http://dx.doi.org/10.1016/j.seizure.2015.07.018
1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reThe most common adverse effects are related to the central
nervous system, including dizziness, fatigue, headache, diplopia,
nystagmus and ataxia [1,2].
After administration oxcarbazepine is rapidly metabolized
via reduction to 10,11-dihydro-10-hydroxy-carbazepine (mono-
hydroxy-derivate, MHD), it is primary clinically relevant metabolite.
There is a linear relationship between the OXC dosage and the MHD
serum concentrations [1,3]. Whether there is a signiﬁcant correla-
tion between MHD concentration in serum and efﬁcacy and
tolerability of OXC therapy is still a matter of debate. Different
therapeutic ranges of MHD are cited and especially the mentioned
upper limits of serum levels showed a considerable variation
between 20 and 40 mg/ml [1,4–9].
The aim of this study was to investigate the relationship
between mono-hydroxy-carbazepine serum levels and the occur-
rence of adverse effects in patients on OXC monotherapy.served.
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group of patients treated with OXC as monotherapy with or
without adverse effects.
2. Methods
The therapeutic drug monitoring (TDM) database of the
Laboratory of the Epilepsy Research Society at the Epilepsy Center
Bethel (Bielefeld) was analyzed with regard to OXC dosages, MHD
serum concentrations and the occurrence and kind of AEs in
patients on OXC monotherapy. As part of clinical routine, serum
levels are determined in case of AEs as well as at the beginning or
before the end of in-patient treatment. Blood samples have to be
accompanied by laboratory order form carrying detailed informa-
tion about the medication and AEs, in case of occurrence.
In addition, further data were extracted, e.g. the pharmaceutical
drug formulation of OXC, date of blood sampling, gender, age and
body weight of the patients. MHD serum levels collected for TDM
were determined between 2005 and 2010. Almost all patients were
inpatients of the Bethel Epilepsy Centre (Bielefeld, Germany), a
tertiary reference center for epilepsy. Just ﬁve patients were under
out-patient care of the epilepsy center.
In total, 990 MHD serum levels under OXC monotherapy were
identiﬁed by searching the laboratory database. OXC monotherapy
as well as all on the laboratory order forms reported AEs were
veriﬁed by checking patients’ medical record and missing
information of the above mentioned data was completed, if
possible. Cases with an incomplete data set were excluded from
further evaluation.
Furthermore, children younger than 6 years of age were
excluded as adverse effects reported by children below the age of
6 were assumed as not reliable. Hence, 893 blood samples of
442 patients were included in this retrospective study. The study
was conducted in accordance with the Gesundheitsdatenschutz-
gesetz (GDSG NRW, German law of healthcare data protection).
2.1. Determination of MHD serum concentrations
For the determination of MHD serum concentrations (sum of R-
and S-enantiomers) a high-performance liquid chromatographic
(HPLC) method with UV detection was used. The serum samples
(100 ml) were mixed with the extraction solution, i.e. 200 ml of
acetonitrile and methanol (9:1) containing the internal standard
ETB = ethyl-tolyl-barbituric acid (all from Sigma–Aldrich, Tauf-
kirchen, Germany). The proteins were precipitated and after
centrifuging the supernatant ﬂuid transferred into microvials. The
chromatographic separation was carried out on a HP 1090 LC
(Agilent, Waldbronn, Germany) apparatus with a Kromasil C18,
5 mm, 250  4 mm HPLC column. A gradient elution with
acetonitrile and a phosphate buffer (pH 4.5) was used at 75 8C
and the wavelength for UV detection was 207 nm. The lower limit
of detection was 0.5 mg/ml and the limit of linearity was found
with 90 mg/ml for MHD. The coefﬁcient of variation (day to day) of
the method was below 3%.
The accuracy of the determination of AED serum concentra-
tions, including MHD, is regularly veriﬁed and certiﬁed by external
quality assessment (participation in interlaboratory comparisons
of three different institutes).
2.2. Statistical evaluation
For analyzing the occurrence of AE in relation to MHD serum
levels and OXC dosages, Kaplan Meier estimates (mean value,
median and standard errors) for the lowest MHD concentration
and lowest OXC dosages at which an AE occurred (mean value,
median and standard errors) were computed.In most patients no AE occurred and therefore the (lowest)
MHD level or OXC dosage at which AE would occur are unknown.
However, in these patients data on the highest MHD level and
highest OXC dosage without AE are available and this kind of
‘‘censored’’ data should be considered in the statistical analysis.
Therefore, we used methods originally developed for survival
analysis (Kaplan Meier estimates, Kaplan–Meier, log rank tests) to
describe and analyze the occurrence of AE dependent on MHD
levels.
Log-ranks tests were performed to check whether the MHD
serum levels or MHD dosages at which AEs occurred were
dependent on gender, age of patients and pharmaceutical formula-
tion of OXC. In some patients two or more MHD determinations were
assessed; however, for the statistical analyses mentioned above only
the highest serum level without AE (‘‘censored’’ values) or, in case of
AE, the lowest serum level at which an AE (‘‘event’’) occurred was
included.
In addition, a generalized estimating equation (GEE) model was
used to investigate the effect of MHD serum levels, OXC dosage,
pharmaceutical formulation of OXC, gender and age (<18 vs. 18
years) on the probability of the occurrence of AE (speciﬁcations:
binominal distribution, logit link function, independent working
matrix structure). Wald-test was used for testing signiﬁcance of
the factors mentioned above. In contrast to usual logistic
regression, in the GEE model using a logistic link function repeated
measurements of patients may be included. Thus, for GEE all
893 blood samples of 442 patients were analyzed.
More details of the GEE approach of are described, for example,
by Fahrmeir et al. [10].
Statistical signiﬁcance was set at p < 0.05 (two-sided, if not
mentioned otherwise). For statistical analyzes IBM SPSS for
Windows 20.0 was used.
3. Results
The patients’ characteristics, daily OXC doses, number of daily
drug administrations, number of trough level determinations,
mean MHD serum concentrations and OXC doses per kg body
weight of patients with AEs (n = 78) and without AEs (n = 364) are
summarized in Table 1. In 251 patients (56.8%) OXC dosage was
stable for more than 14 days, in 96 patients (21.7%) dose has been
changed between the last 4 to 14 days and in 95 patients (21.5%)
dose adjustments have been conducted within the past three days
(steady state cannot be assumed in these cases). At least one AE
was reported in 78 (17.6%) of the 442 patients. The type of AE is
summarized in Table 2.
The relationship between the occurrence of an AE and the
related MHD serum levels and OXC dosages per kg body weight,
respectively, is illustrated in Fig. 1a and b by using Kaplan–Meier
plots. At MHD serum concentrations of 25.3 mg/ml, 30.0 mg/ml,
35.7 mg/ml, and 43.7 mg/ml, 10%, 25%, 50% and 75% of patients,
respectively, experienced at least one AE. The corresponding OXC
doses were 24.0 mg/kg, 33.1 mg/kg, 50.3 mg/kg and 62.3 mg/kg.
The estimated mean and median MHD serum levels at which an AE
occurred in 50% of the patients were 37.9 mg/ml (standard error
1.43) and 35.7 mg/ml (standard error 0.70) respectively. Accord-
ingly, the estimated mean and median OXC dose per kg were
47.3 mg/kg (standard error 1.49) and 50.3 mg/kg (standard error
4.05), respectively.
The Log-rank tests (Table 3) indicated that the age of patients
(<18 years vs. 18 years) had a signiﬁcant effect on the MHD
serum levels and OXC dosages per body weight at which AEs
occurred (p = 0.006, p < 0.001, respectively), whereas the phar-
maceutical formulation had a signiﬁcant effect only on OXC
dosages related to AE (p = 0.010), but not on MHD serum levels
(p = 0.125). The effect of gender was not signiﬁcant.
Table 1
Patients’ characteristics.
N. Total (%) Mean SD Min. Max.
Gender Male 241 54.8
Female 201 45.2
Age (years) 442 29.6 15.76 6.0 79.9
Weight (kg) 442 70.5 23.00 16.9 134.0
Drug (dose per day) Timox1/Trileptal1 324 73.3 1610 624 225 3450
b.i.d. 275 62.2 1562 624 225 3450
t.i.d. 49 11.1 1876 560 750 3000
Apydan1 118 26.7 1814 665 450 3600
b.i.d. 116 26.2 1806 663 450 3600
t.i.d. 2 0.5 2250 849 1650 2850
Number of MHD With AEsa 29 37.2
trough serum conc. Without AEsb 297 81.6
MHD serum conc. (mg/ml) With AEsc 78 17.6 27.9 8.55 5.4 57.5
Without AEsd 364 82.4 21.8 7.91 3.3 46.3
OXC dosage (mg/kg) With AEse 78 17.6 27.1 9.73 8.1 62.3g
Without AEsf 364 82.4 25.0 10.83 4.6 62.5g
Abbreviations: conc.: concentration, MHD: mono-hydroxy-derivate, OXC: oxcarbazepine, AEs: adverse effects.
a Serum conc. was determined as trough level (immediately before drug intake) in 29 (37.2%) of 78 patients with AEs.
b Serum conc. was determined as trough level (immediately before drug intake) in 297 (81.6%) of 364 patients without AEs.
c lowest measured MHD serum conc. associated with an AE in patients with AEs.
d highest measured MHD serum conc. in patients without any AE.
e lowest body weight adjusted OXC dosage associated with an AE in patients with AEs.
f highest body weight adjusted OXC dosage in patients without any AE.
g In total, 9 patients were treated with OXC dosages higher than 50 mg/kg (range 50.3–62.5 mg/kg) of whom 8 were younger patients (<18 years). Seven of the 8 younger
patients and the adult patient tolerated these high dosages. Six of the 7 patients without AEs were treated with extended-release formulations and one patient (child) without
AEs was treated with an immediate-release formulation.
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higher MHD serum levels as well as higher OXC dosages than adults
(18 years). Furthermore, Fig. 3a and b illustrate that patients
treated with extended-release OXC formulation tolerated higher
body weight adjusted dosages compared to patients treated with
immediate-release formulations, whereas MHD serum levels at
which AEs occurred were not dependent on the OXC formulation.
Multivariate GEE including all 893 blood samples conﬁrmed the
signiﬁcant effect of MHD serum levels, pharmaceutical formula-
tion and age (<18 years vs. 18 years) on the occurrence of AEs,
whereas the body weight adjusted dosage of OXC had no additional
signiﬁcant inﬂuence on the probability of the occurrence of an AE
(Supplementary Table A).
4. Discussion
In total, at least one adverse effect was reported in 78 patients
(17.6%). The reported AEs were asserted and documented by
neurologists or epilepsy specialist nurses on the laboratory orderTable 2
Summary of adverse events in 78 patients.
No. of
patients
Patients with
AE (%) (n = 78)
Total of patients
(%) (n = 442)
Dizziness 46 59.0 10.4
Diplopia 25 32.1 5.7
Nystagmus 25 32.1 5.7
Ataxia 11 14.1 2.5
Fatigue 9 11.5 2.0
Nausea 6 7.7 1.4
Headache 5 6.4 1.1
Vomiting 4 5.1 0.9
Others* 6 7.7 1.4
Abbreviation: AE: adverse effect.
* Drowsiness, xerostomia, concentrating impairment, memory impairment,
eczema, dysphasia.form. Compared with other studies [6,11–13], the rate of 17.6% of
patients suffering from adverse effects is relatively small. However,
in this study only clinical symptoms, predominately central
nervous system (CNS) related symptoms, of an OXC overdose
were considered, but not lab results, such as hyponatremia, which
is also a frequently mentioned AE [6]. Additionally most of the
studies are based on OXC as adjunctive therapy and serum levels
were assessed for study reasons and not as part of clinical routine
[11,13–15].
Furthermore, some studies report that side effects of OXC are
observed most frequently within the ﬁrst weeks after changes of
therapy or increase of dosage [13,15]. These ﬁndings are in
accordance with our results. In our study, AEs were reported in 38
(40.0%) of 95 patients with changes of OXC dosage within the past
4 days compared to 23 (24.0%) of 96 patients with changes of OXC
dosages between the last 4 and 14 days and compared to 17 (6.8%)
of 251 patients with OXC dosages unchanged for more than
2 weeks (p < 0.001, Fisher’s exact test). Therefore, the high rate of
patients on a stable (long-term) treatment with OXC in our study
contributes to the relatively low prevalence of side effects
compared those reported in clinical studies. Bourgeois and D’Souza
[15] also mentioned that clinical studies compared to clinical
practice overestimate the rate of AEs though the prevalence
determined in this surveillance has to be conﬁrmed or refuted by
further real-life data.
Respecting the type of AEs, we found the expected adverse drug
reactions typical for OXC, or rather voltage-gated sodium channel
blockers (VGSC) in general, which are related to the central
nervous system (dizziness, fatigue, diplopia, nystagmus, headache
and ataxia) or digestive system (nausea and vomiting), as most
frequent [8,11,13,14,16,17].
Furthermore, our ﬁndings conﬁrm that AEs of OXC are
signiﬁcantly related to MHD serum levels or OXC dosages in
accordance with the results of Barcs et al. or Striano et al.
[8,11]. The Kaplan Meier plots indicate especially that at MHD
Fig. 1. (a and b) Kaplan–Meier plots of the cumulative probability of adverse effects
(AEs) related to MHD (mono-hydroxy-derivate) serum concentration and body
weight adjusted dosage of OXC (oxcarbazepine).
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the relationship to OXC dosage is less distinctive.
In case of AEs, only 29 (37.2%) of the corresponding MHD serum
levels were trough levels (blood samples taken immediately before
drug intake) compared to 297 (81.6%) corresponding MHD serum
levels without AEs. This indicates that most AEs were related to
increasing or peak MHD serum concentrations after drug intake.
This seems to be true especially for vestibulo-cerebellar AEsTable 3
Results of the Log-Rank test for gender, age and pharmaceutical formulation.
N. of patients Mean conc.
(mg/ml)
Standa
error
Gender
Male 241 42.7 2.61 
Female 201 34.5 0.96 
Age
<18 years 128 44.3 3.82 
18 years 314 34.8 0.88 
Drug
TimoxW/TrileptalW 324 37.4 1.51 
ApydanW extended-release 118 35.0 1.04 
Abbreviations: N: number of patients, conc.: concentration, sig.: signiﬁcance, y: years including dizziness, diplopia, nystagmus or ataxia. Whereas in case
of vestibulo-cerebellar AEs, only 19 (30.2%) of the 63 corresponding
MHD serum concentrations were trough levels, this was true for 10
(66.7%) of 15 MHD serum concentrations concerning other AEs, e.g.
tiredness, headache (p = 0.016, Fisher’s exact test).
It should be noticed that the diurnal ﬂuctuation of the MHD
concentration may also have an impact on the tolerability of OXC
[18–20]. Even if the daily ﬂuctuation of MHD serum levels is
generally described as relatively small in most cases, high
individual variations are possible [21]. These considerations
correspond to our ﬁndings concerning the pharmaceutical
formulation of OXC. Our results indicate that of the extended-
release formulation higher body weight adjusted doses are better
tolerable than comparable OXC dosages of the immediate-release
formulations, whereas we found no difference in relation to the
tolerated MHD serum level. Similar results have been reported by
Steinhoff et al., Leppik and Hovinga and French et al. ([12,18];
Steinhoff and Wendling, 2009; [20]). Even if not directly object of
this investigation, studies have demonstrated that intermitted AEs
could also be related to ﬂuctuations of OXC levels as prodrug of
MHD. These as well could markedly be reduced by using extend-
release formulations and therefore also can be a reason for better
tolerability of higher doses by avoiding immediate-release
formulations [17,20,22].
Furthermore, our results illustrate that younger patients (<18
years) tolerate higher MHD serum levels as well as higher body
weight adjusted OXC dosages compared to adult patients (18
years). Seven patients tolerated even doses above 50 mg/kg (six on
a b.i.d. regimen of the extended-release formulation, one on t.i.d.
regimen of an immediate-release formulation) of which 6 have
been younger than 18 years of age. So far, several studies
investigated the impact of age on pharmacokinetics of MHD,
efﬁcacy and tolerability. But only a few studies considered patients
on OXC monotherapy and in most cases the compared age groups
were deﬁned differently. Further, most studies focused on special
groups like younger children or elderly patients. But, in spite of
differences in the comparing age groups, our results are in
accordance with the ﬁnding of various studies [1,23,24] indicating
that younger children require higher dosages in order to attain
adequate serum levels whilst maintaining tolerability. This was
conﬁrmed in our study as well. The calculated MHD level-to-dose
ratio (MHD serum concentration/OXC dose/body weight) was
about 20% lower for patients aged under 18 years compared to
those aged over 18 years (0.79  0.23 [mg/ml]/[mg/kg] vs.
1.04  0.36 [mg/ml]/[mg/kg], p < 0.001).
A contrary effect was described for elderly patients [1,25,26]
which, however, could not be investigated in this study due to the
small number of patients aged over 65 (<2% of the patients).
As far as we know, there have been no investigations
concerning gender as a potential inﬂuencing factor on tolerabilityrd Sig. Mean dose
per kg (mg/kg)
Standard error Sig.
0.110 50.6 1.87 0.082
44.5 2.07
0.006 55.8 1.86 <0.001
38.2 1.29
0.125 44.1 2.10 0.010
53.4 2.38
of age.
Fig. 2. (a and b) Kaplan–Meier plots of the cumulative probability of adverse effects
(AEs) related to MHD (mono-hydroxy-derivate) serum concentration and body
weight adjusted dosage differentiated by age groups.
Fig. 3. (a and b) Kaplan–Meier plots of the cumulative probability of adverse effects
(AEs) related to MHD (mono-hydroxy-derivate) serum concentration and body
weight adjusted dosage differentiated by pharmaceutical products.
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difference in tolerability of OXC between men and women.
The above discussed effects of MHD serum levels, pharmaceu-
tical formulation of OXC, and age (<18 years vs. 18 years) on the
tolerability of OXC were conﬁrmed by GEE. Finally, it should be
mentioned that due to a different ratio of S- and R-enantiomers
these results should not be generalized to patients receiving
eslicarbazepine.
4.1. Limitations
Our study has several limitations. First of all, this was a
retrospective study, accordingly there was no ﬁxed schedule–
neither for the minimum or the maximum dose of OXC nor for the
time of taking blood samples. Furthermore, the reporting of AEs
was dependent on patient’s subjective perception and abnormal
lab values were not considered. In some cases, determined serum
levels could differ from the actual serum level at ﬁrst appearance of
the AE as blood sampling was lagged. But the number of these cases
can considered being small as, apart from ﬁve, all patients were
inpatients of an epilepsy center and timely blood sampling is part
of clinical routine.5. Conclusion
Our results indicate that the occurrence of adverse effects,
especially those related to the central nervous or digestive system
was signiﬁcantly related to the MHD serum level. Children and
younger patients tolerated higher body weight adjusted doses of
OXC as well as higher MHD serum levels compared to adults.
Furthermore, higher doses of the extended-release formulation of
OXC seem to be better tolerated than identical doses of immediate-
release formulations, probably due to lower diurnal ﬂuctuations of
MHD serum levels.
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